Precipio Announces Q3-2026 Financial Results
Operating cash flow reached $0.6 million, while adjusted EBITDA remained positive but fell from the prior-year quarter.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Precipio (NASDAQ: PRPO) reported third-quarter 2026 revenue of $7.3 million, with growth in both its product and pathology businesses. Revenue rose 8% from $6.8 million in Q3-2025 and increased from $7.0 million in Q2-2026. Product revenue reached $1.0 million, up 40% year over year, while pathology revenue reached $6.3 million, up 5%.
GAAP net income was $0.0 million, compared with a $0.1 million loss a year earlier. Adjusted EBITDA, a non-GAAP earnings measure excluding certain expenses, was $0.4 million versus $0.5 million a year earlier and $0.4 million in Q2-2026. Operating cash flow was $0.6 million, and total cash increased by $0.5 million during the quarter. Quarter-end cash exceeded $3.5 million, versus $2.3 million a year earlier. Management believes its cash position supports accelerating commercialization of existing products.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointQ3-2026 revenue of $7.3M rose 8% year over year and increased from $7.0M in Q2-2026.
- Moderate pointQuarter-end cash exceeded $3.5M, versus $2.3M a year earlier, after increasing $0.5M during the quarter.
- Minor pointProduct revenue of $1.0M rose 40% year over year from $0.7M and exceeded Q2-2026's $0.9M.
- Minor pointPathology revenue of $6.3M rose 5% year over year from $6.0M and exceeded Q2-2026's $6.1M.
- Minor pointGAAP net income of $0.0M improved from a $0.1M loss in Q3-2025.
2 minor points
- Minor pointOperating cash flow was $0.6M in Q3-2026.
- Minor point. Forward-looking: it has not happened yet and may not happen.Existing-product commercialization could accelerate with the quarter-end cash position, management believes.
Negative
- Moderate pointAdjusted EBITDA of $0.4M declined from $0.5M in Q3-2025 and matched Q2-2026.
Details
Market Reaction – PRPO
On Nov 10, the day this news came out, the latest delayed price for PRPO is 4.86% below the previous close. Our momentum scanner has recorded 6 alerts for this stock so far that day. The latest delayed price is $22.50.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Revenue
- $7.3M; up 8% year-over-year
- Q3 2026
- Product revenue
- $1.0M; up 40% year-over-year
- Q3 2026
- Pathology revenue
- $6.3M; up 5% year-over-year
- Q3 2026
- Adjusted EBITDA
- $0.4M
- Q3 2026; versus $0.5M in Q3 2025 and $0.4M in Q2 2026
- Cash flow from operations
- $0.6M
- Q3 2026
- Quarter-end cash balance
- Exceeding $3.5M
- At the end of Q3 2026; versus $2.3M in Q3 2025
Previous Earnings Reports
-
Reported $7.0M revenue, positive adjusted EBITDA and $0.7M operating cash flow.
-
Reported $6.8M revenue and positive adjusted EBITDA of $469K.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
ebitda financial
non-gaap financial measure financial
stock-based compensation financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Record quarterly revenue, positive Adjusted EBITDA, and strong operating cash flow - all position Precipio for accelerated future growth
NEW HAVEN, Conn., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces third-quarter financial results for the quarter ending September 30, 2026.
Below are some of the key financial performance metrics for the Company. For additional results, please see the Company’s Form 10-Q filed today.
- Revenue –
$7.3M , up8% year-over-year from$6.8M in Q3-2025 and from$7.0M in Q2-2026. This comprises$1.0M in product revenue (up40% year-over-year from$0.7M in Q3-2025, and$0.9M in Q2-2026), and$6.3M in pathology revenue (up5% year-over-year from$6.0M in Q3-2025, and$6.1M in Q2-2026). - Adjusted EBITDA –
$0.4M vs.$0.5M in Q3-2025 and$0.4M in Q2-2026. - Cash flow - Cash flow from operations was
$0.6M in Q3-2026; total cash increased by$0.5M , resulting in an end-of-quarter cash balance exceeding$3.5M , vs$2.3M in Q3-2025.
“In the third quarter we continued to strengthen our financial position, delivering record revenue while maintaining positive Adjusted EBITDA and generating cash from operations,” said Ilan Danieli, CEO of Precipio. “Our pathology business continues to provide a strong operational and financial foundation for growth, while also serving as the clinical development and validation platform for our proprietary diagnostic products. With more than
Additional information and a more in-depth discussion on the Company’s Q3-2026 performance will be provided in the shareholder call today at 5 PM ET. The call will include remarks by management on the Company’s core business, followed by a moderated Q&A session.
EBITDA and Adjusted EBITDA Reconciliation and Explanation
EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a non-GAAP financial measure that is widely used to evaluate operational performance and pre-tax profitability of emerging growth companies like ours. Management believes Adjusted EBITDA provides investors with a useful perspective on the Company’s financial performance, particularly where non-cash amortization has an important impact on profitability.
Adjusted EBITDA as we define it modifies EBITDA by excluding the non-cash costs of employee stock options and unusual non-operating income and expense. Below is a reconciliation of Net Income, EBITDA and Adjusted EBITDA for the third quarter of 2026 and 2025:
| ($ in millions, unaudited) | Q3-26 | Q3-25 | |||
| Net income/(loss) (GAAP) | $ | 0.0 | $ | (0.1 | ) |
| Adjustments to net income/(loss): | |||||
| Interest expense, net | $ | 0.0 | $ | 0.0 | |
| Income taxes | $ | 0.0 | $ | 0.0 | |
| Depreciation | $ | 0.1 | $ | 0.1 | |
| Amortization of intangibles | $ | 0.2 | $ | 0.3 | |
| EBITDA (non-GAAP) | $ | 0.3 | $ | 0.3 | |
| Further Adjustments to EBITDA | |||||
| Stock-based compensation expense | $ | 0.1 | $ | 0.2 | |
| Other significant (income) expenses | $ | 0.0 | $ | 0.0 | |
| Adjusted EBITDA (non-GAAP) | $ | 0.4 | $ | 0.5 | |
About Precipio
Precipio is a healthcare biotechnology company focused on cancer diagnostics. Our mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services. Our products and services deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in our laboratory where we design, test, validate, and use these products clinically, improving diagnostic outcomes. Precipio then commercializes these technologies as proprietary products that serve the global laboratory community and further scale Precipio’s reach to eradicate misdiagnosis.
Availability of Other Information About Precipio
For more information, please visit the Precipio website at https://www.precipiodx.com/ or follow Precipio on X (formerly Twitter) (@PrecipioDx) and LinkedIn (Precipio) and on Facebook. Investors and others should note that we communicate with our investors and the public using our company website (https://www.precipiodx.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the targets set herein and related timing. Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, adjusted EBITDA, plans, objectives, expectations, growth or profitability and our potential to reach financial independence are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “will,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and our other reports filed with the U.S. Securities and Exchange Commission. Any such forward-looking statements represent management’s estimates as of the date of this press release only. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Inquiries: investors@precipiodx.com +1-203-787-7888 Ext. 523
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Precipio's Q3-2026 revenue and GAAP earnings?
Precipio reported $7.3M in revenue and $0.0M in GAAP net income for the quarter ended September 30, 2026. Revenue increased 8% from $6.8M in Q3-2025, when the company reported a $0.1M net loss.
How does Precipio calculate adjusted EBITDA?
Precipio calculates adjusted EBITDA by excluding interest, taxes, depreciation and amortization from net income, then excluding non-cash employee stock-option costs and unusual non-operating income and expenses. Its Q3-2026 reconciliation shows $0.3M of EBITDA and a $0.1M stock-based compensation adjustment, producing $0.4M of adjusted EBITDA.